- Login
- Register & Subscribe
- Language: EN FR DE
Finance, Grants, Deals
Sanofi acquires US firm developing kinase inhibitors
Wednesday 30 June 2010
Sanofi-Aventis SA is acquiring TargeGen Inc, a privately held US company that specialises in developing small-molecule kinase inhibitors for treatment of haematological malignancies.
Location
France
SV Life Sciences raises $523 million for fifth fund
Tuesday 29 June 2010
SV Life Sciences said that it has raised more than $523 million for its fifth international life sciences fund which will focus on providing start-up, early stage and expansion capital to life science companies in the US and Europe.
Location
United States
See map: Google Maps
MorphoSys in-licenses antibody targeting CD19
Monday 28 June 2010
MorphoSys AG has agreed to pay $13 million for rights to an anti-CD19 monoclonal antibody that is scheduled to start a Phase 1 study in cancer patients in the US shortly. It is the company’s first in-licensing deal for a clinical compound.
Location
Germany
See map: Google Maps
Gilead to pay $120 million for kinase biology company
Saturday 26 June 2010
Gilead Sciences Inc has agreed to pay up to $120 million to acquire CGI Pharmaceuticals Inc, a privately-held US company with a library of small molecule kinase inhibitors. CGI’s lead preclinical compound may have application in RA.
Location
United States
See map: Google Maps
Sanofi-Aventis invests in new diabetes agent
Friday 25 June 2010
Sanofi-Aventis SA has entered into a licensing agreement with Metabolex Inc of the US to develop a novel treatment for Type 2 diabetes that targets the G protein-coupled receptor 119. The deal could be valued at $375 million if a product is commercialised.
Location
France
Crucell and J&J to investigate RSV vaccine
Friday 25 June 2010
Crucell NV has announced the start of a project to discover a universal prophylactic vaccine against the respiratory syncytial virus (RSV), a cause of serious respiratory illnesses in infants and children. It will be working with a unit of Johnson & Johnson.
Location
Netherlands
See map: Google Maps
Diamyd partners its diabetes vaccine with J&J unit
Wednesday 23 June 2010
Diamyd Medical AB has partnered its lead antigen-based therapy for the treatment and prevention of Type1 diabetes with Ortho-McNeil-Janssen Pharmaceuticals Inc (OMJPI), a unit of Johnson & Johnson.
Location
Sweden
Sanofi and Regulus form microRNA alliance
Tuesday 22 June 2010
Sanofi-Aventis SA and Regulus Therapeutics Inc have formed a global alliance to develop and commercialise medicines based on microRNA, a class of small ribonucleic acid molecules that regulate gene expression.
Location
France
Alliance formed to research anti-cancer stem cell therapies
Thursday 17 June 2010
OncoMed Pharmaceuticals Inc of California and Bayer Schering Pharma AG of Berlin have entered into a global alliance to develop therapies that attack cancer stem cells.
Location
Germany
See map: Google Maps
Pharnext raises €4.8 million for trial of combination drug
Friday 11 June 2010
A three-year-old French biopharmaceutical company, Pharnext SAS, has raised €4.8 million in a Series A round to take a new combination drug into the clinic to treat an inherited neurological disorder known as Charcot-Marie-Tooth disease.
Location
France
Select a News Category
Recent Appointments
Tim Edwards elected chairman of BIA
Tuesday September 7 2010
Index Ventures appoints antibody expert as partner
Friday September 3 2010
Colin Stewart appointed CEO at Amarin
Friday August 20 2010
Karl Keegan nominated as CFO of Pharming
Friday August 20 2010
Axel Müller becomes CEO at SkyePharma
Thursday August 19 2010